Epizyme gets accelerated approval for drug to treat rare sarcoma
The agency gave accelerated approval to Tazverik in epithelioid sarcoma, a rare but serious connective tissue cancer. The company is also seeking approval for the drug, an EZH2 inhibitor, for the blood cancer follicular lymphoma.